Author:
LaBute Brayden,Fong Jackie,Ziaee Farinaz,Gombar Robert,Stover Mathew,Beaudin Terry,Badalova Maria,Geng Qiudi,Corchis-Scott Ryland,Podadera Ana,Lago Kyle,Xu ZhenHuan,Lim Fievel,Chiu Felix,Fu Minghua,Nie Xiaofeng,Wu Yuanmin,Quan Corrina,Hamm Caroline,McKay R. Michael,Ng Kenneth,Porter Lisa A.,Tong Yufeng
Abstract
AbstractCOVID-19 has been a global public health and economic challenge. Screening for the SARS-CoV-2 virus has been a key part of disease mitigation while the world continues to move forward, and lessons learned will benefit disease detection beyond COVID-19. Saliva specimen collection offers a less invasive, time- and cost-effective alternative to standard nasopharyngeal swabs. We optimized two different methods of saliva sample processing for RT-qPCR testing. Two methods were optimized to provide two cost-efficient ways to do testing for a minimum of four samples by pooling in a 2.0 mL tube and decrease the need for more highly trained personnel. Acid-pH-based RNA extraction method can be done without the need for expensive kits. Direct Lysis is a quick one-step reaction that can be applied quickly. Our optimized Acid-pH and Direct Lysis protocols are reliable and reproducible, detecting the beta-2 microglobulin (B2M) mRNA in saliva as an internal control from 97 to 96.7% of samples, respectively. The cycle threshold (Ct) values for B2M were significantly higher in the Direct Lysis protocol than in the Acid-pH protocol. The limit of detection for N1 gene was higher in Direct Lysis at ≤ 5 copies/μL than Acid-pH. Saliva samples collected over the course of several days from two COVID-positive individuals demonstrated Ct values for N1 that were consistently higher from Direct Lysis compared to Acid-pH. Collectively, this work supports that each of these techniques can be used to screen for SARS-CoV-2 in saliva for a cost-effective screening platform.
Funder
Canadian Institutes of Health Research
Publisher
Springer Science and Business Media LLC